Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA approves Blenrep for relapsed or refractory multiple myeloma

2.

Researchers identify a novel biomarker linked to renal cancer recurrence

3.

'Sugar' signatures help identify and classify pancreatic cancer cell subtypes

4.

Neural networks and label-free microscopy enable accurate detection of pancreatic tumors

5.

A pilot study investigates a novel strategy for lowering anxiety and enhancing post-stem cell transplant quality of life.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot